Northern Trust
CNTA

Northern Trust’s Centessa Pharmaceuticals CNTA Stock Holding History

Northern Trust’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,785
Closed -$227K – 4425
2025
Q1 		$227K Buy
+15,785
New +$258K ﹤0.01% 3903
2022
Q1 		– Sell
-8,884
Closed -$100K – 4762
2021
Q4 		$100K Buy
+8,884
New +$120K ﹤0.01% 4425
2021
Q3 		– Sell
-18,400
Closed -$409K – 4669
2021
Q2 		$409K Buy
+18,400
New +$432K ﹤0.01% 3803

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust's CNTA Position: Q2 2025 in Review

Northern Trust sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 15,785 shares — an estimated $227K sold.

Northern Trust first reported a position in CNTA in Q2 2021 and held it in 3 quarters. The position peaked at $409K in Q2 2021. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Northern Trust reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Northern Trust sold 15,785 Centessa Pharmaceuticals shares in Q2 2025, an estimated $227K.
  • Northern Trust first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Northern Trust's Centessa Pharmaceuticals position peaked at $409K in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Northern Trust's 13F filing for Q2 2025, filed 13 Aug 2025.